Literature DB >> 1586748

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

A J Barrett1, M M Horowitz, R C Ash, K Atkinson, R P Gale, J M Goldman, P J Henslee-Downey, R H Herzig, B Speck, F E Zwaan.   

Abstract

Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.

Entities:  

Mesh:

Year:  1992        PMID: 1586748

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Hagop Kantarjian
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 2.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

3.  Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Authors:  Nelli Bejanyan; Mei-Jie Zhang; Hai-Lin Wang; Aleksandr Lazaryan; Marcos de Lima; David I Marks; Brenda M Sandmaier; Veronika Bachanova; Jacob Rowe; Martin Tallman; Partow Kebriaei; Mohamed Kharfan-Dabaja; Robert Peter Gale; Hillard M Lazarus; Celalettin Ustun; Edward Copelan; Betty Ky Hamilton; Gary Schiller; William Hogan; Shahrukh Hashmi; Matthew Seftel; Christopher G Kanakry; Richard F Olsson; Rodrigo Martino; Wael Saber; H Jean Khoury; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-21       Impact factor: 5.742

4.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Authors:  K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 5.  Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.

Authors:  Hiroatsu Iida; Hiroshi Sao; Kenjiro Kitaori; Seiichi Gotoh; Makoto Yazaki; Seiji Kojima; Atsushi Wakita; Yasuo Morishima; Yoshihisa Kodera; Yoshihisa Morishita
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

6.  The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yi Zhou; Rebecca Slack; Jeffrey L Jorgensen; Sa A Wang; Gabriela Rondon; Marcos de Lima; Elizabeth Shpall; Uday Popat; Stefan Ciurea; Amin Alousi; Muzaffar Qazilbash; Chitra Hosing; Susan O'Brien; Deborah Thomas; Hagop Kantarjian; L Jeffrey Medeiros; Richard E Champlin; Partow Kebriaei
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-15

7.  Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.

Authors:  Makoto Yoshimitsu; Hiroshi Fujiwara; Atsuo Ozaki; Heiichiro Hamada; Kakushi Matsushita; Naomichi Arima; Chuwa Tei
Journal:  Int J Hematol       Date:  2008-08-12       Impact factor: 2.490

Review 8.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

Review 9.  Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Ryuzo Ohno
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 10.  Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Masamitsu Yanada; Ryuzo Ohno; Tomoki Naoe
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.